NeoGenomics, Inc

NeoGenomics is a U.S.-based cancer diagnostics company that provides oncology testing and consultative pathology services to help clinicians identify, classify, and monitor cancer. It operates a network of cancer-focused laboratories in the United States and the United Kingdom and also serves pharmaceutical customers with clinical trial testing, biomarker analysis, and oncology data solutions.

−11,0 %

43,2 %

−14,9 %

+10,1 %

4.26

3.94

— NeoGenomics, Inc
%
Clinical oncology testing55% Diagnostic laboratory testing used by physicians to detect, classify, and monitor cancer.
Molecular and NGS testing20% Next-generation sequencing and molecular assays used for therapy selection and disease characterization.
MRD testing10% Minimal residual disease testing used to detect very low levels of cancer after treatment.
Professional interpretation and consultative services7% Physician and molecular expert review of laboratory results, including second-opinion pathology.
Pharmaceutical development services5% Laboratory testing, biomarker analysis, and study support for sponsor-led clinical research.
Oncology data solutions3% Licensing of de-identified oncology data to pharma and biotech customers for research and targeting.

NeoGenomics sells primarily to healthcare providers that need specialized cancer testing and expert interpretation,...

  • Community oncology practicesprimary

    Buy routine and advanced cancer tests, MRD assays, and consultative support to manage patients locally.

  • Hospitals and hospital pathology labsprimary

    Use NeoGenomics for specialized reference testing, complex case review, and overflow capacity.

  • Pathology and reference laboratoriessecondary

    Send difficult specimens for advanced molecular testing and expert interpretation.

  • Academic medical centerssecondary

    Buy specialized oncology diagnostics for complex cases, research, and precision medicine programs.

  • Pharmaceutical and biotech sponsorssecondary

    Purchase lab services, biomarker analysis, and oncology data for clinical trials and drug development.

NeoGenomics operates mainly in the United States, where most testing, sales, and customer relationships are...

  • •Primary operations and revenue are in the United States
  • •Laboratories operate in Florida, California, North Carolina, New Jersey, and Texas
  • •Full-service sample-processing lab in Cambridge, United Kingdom
  • •Some international samples and employee data create GDPR/privacy exposure
  • •U.S. lab network supports specimen logistics and turnaround times

NeoGenomics is focused on expanding share in oncology diagnostics through new tests, especially therapy selection and...

01
Launch next-generation precision diagnostic testsshort-term

New therapy-selection and MRD assays support higher-value testing and strengthen the oncology menu.

02
Expand community oncology presencemedium-term

Community oncology is a key growth channel where broad menus and service quality can win share.

03
Optimize customer experience and operationsshort-term

Automation and platform upgrades can improve turnaround times, margins, and retention.

04
Grow pharma development and data solutionsmedium-term

Sponsor services and data licensing diversify revenue beyond routine clinical testing.

NeoGenomics faces execution risk from rapid scientific change, capacity constraints, and the need to keep launching...

high

Competition and price pressure

The company competes with large reference labs and CROs, which can pressure pricing and win rates.

Scope
Clinical oncology testing and pharma services
Materiality
high
high

Capacity constraints

If lab throughput or staffing cannot keep pace with demand, growth and service levels can suffer.

Scope
Laboratory operations and turnaround times
Materiality
high
high

Technology obsolescence

The company must continually develop or license new testing technologies to stay relevant.

Scope
Molecular testing, NGS, MRD
Materiality
high
high

Cybersecurity and IT disruption

Lab operations depend on LIMS, CRM, and data systems; outages can halt testing and billing.

Scope
Specimen processing, results delivery, billing
Materiality
high
high

Goodwill and intangible asset impairment

Acquisition-related assets depend on future cash flows and can be written down if assumptions weaken.

Scope
Acquired businesses and intangibles
Materiality
high
medium

Regulatory and privacy compliance

Healthcare referral laws, HIPAA, and GDPR can create penalties and operational restrictions.

Scope
U.S. and U.K./EU data and clinical workflows
Materiality
medium
Revenue recognition and accounts receivable
Can affect reported revenue, bad debt, and cash conversion
Goodwill and intangible impairment
Can create large non-cash charges to earnings
Stock-based compensation
Reduces reported profit without immediate cash outflow
Acquisition and integration costs
Affects adjusted EBITDA and GAAP margin comparisons
Amortization of acquired intangibles
Reduces operating income and net income

NEOGENOMICS INC

NEO · Services-Testing Laboratories

Pandox

PNDX-B.ST · Real Estate

NOTE

NOTE.ST · Technology

Transtema Group

TRANS.ST · Telecommunications

RaySearch Laboratories

RAY-B.ST · Health Care

Investment AB Öresund

ORES.ST · Financials

: 28.4.2026